Current status of risk stratification methods in acute coronary syndromes
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Distinguishing which patients with chest pain are at high risk versus which are at low risk remains an important clinical problem despite modern risk stratification strategies. Current approaches often over-utilize hospital resources, yet still miss a significant number of true acute coronary syndromes (ACS). This review focuses on important developments in risk stratification in ACS from 2004 through 2005. Risk models have been developed that use readily available patient characteristics, and head to head comparisons of the various models have been performed to guide clinicians in selecting between the different options. The most powerful models now include measurement of renal function, which has emerged as an important marker of risk. In addition to cardiac troponins, B-type natriuretic peptide (BNP) clearly augments risk prediction, and in the past year serial BNP measurement after discharge has shown promise as a simple way to monitor patient risk following ACS. Newer biomarkers are on the horizon but have not yet established their clinical value. Finally, advances in coronary CT angiography and bedside echocardiography offer hope that noninvasive imaging may play a more important role in early risk stratification in the near future.
- McCaig LF, Burt CW: National Ambulatory Medical Care Survey: 2001 Emergency Department Summary. Advance Data from Vital and Health Statistics; No. 225. Hyattsville, MD: National Center for Health Statistics, 2003.
- Goldman L, Weinberg M, Weisberg M, et al.: A computer derived protocol to aid in the diagnosis of emergency room patients with acute chest pain. N Engl J Med 1982, 307:588–596. CrossRef
- McCarthy BD, Beshansky JF, D#x2019;Agostino RB, et al.: Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study. Ann Emerg Med 1993, 22:579–582. CrossRef
- Pope JH, Aufderheide TP, Ruthazer R, et al.: Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000, 342:1163–1170. CrossRef
- Antman EM, Cohen M, Bernink PJLM, et al.: The TIMI risk score for unstable angina/non-ST elevation MI. JAMA 2000, 284:835–842. CrossRef
- Granger CB, Goldberg RJ, Dabbous OH, et al., for the Global Registry of Acute Coronary Events Investigators: Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003, 163:2345–2353. CrossRef
- Boersma E. Pieper KS, Steyerberg EW, et al., for the PURSUIT Investigators: Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation 2000, 101:2557–2567.
- Goncalves PA, Ferreira J, Aguiar C, et al.: TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005, 26:865–872. CrossRef
- • Yan AT, Jong P, Yan RT, et al.: Clinical trial-derived risk model may not generalize to real-world patients with acute coronary syndrome. Am Heart J 2004, 148:1020–1027.This prospective observational trial compared GRACE and PURSUIT models head to head in 4627 patients and found that although both risk models successfully identified at-risk patients, GRACE showed better calibration overall CrossRef
- • Gibson CM, Dumaine RL, Gelfand EV, et al.: Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials. Eur Heart J 2004, 25:1998–2005.This large retrospective study estimated GFR from patient data at presentation and found a ninefold increase in all-cause mortality between the lowest and highest quartiles of renal function. There was also an increased incidence of three-vessel CAD observed in the lowest quartile of renal function CrossRef
- Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31–41. CrossRef
- Levey AS, Bosch JP, Lewis JB, et al.:A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461–470.
- Levey AS, Greene T, Kusek JW, et al.: A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000, 11:155A.
- Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002, 48:699–707.
- Jernberg T, Lindahl B, James S, et al.: Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004, 110:2342–2348. CrossRef
- Srivathsan K, Showalter J, Wilkens J, et al.: Cardiovascular outcome in hospitalized patients with minimal troponin I elevation and normal creatine phosphokinase. Int J Cardiol 2004, 97:221–224. CrossRef
- Dokainish H, Pillai M, Murphy SA, et al.: Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005, 45:19–24. CrossRef
- Maeda K, Tsutamoto T, Wada A, et al.: Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998, 135:825–832. CrossRef
- Abdullah SM, Khera A, Das SR, et al.: Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of N-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (The Dallas Heart Study). Am J Cardiol 2005, 96:1284–1289. CrossRef
- Bassan R, Potsch A, Maisel A, et al.: B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur Heart J 2005, 26:234–240. CrossRef
- Schnabel R, Rupprecht HJ, Lackner KJ, et al.: Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 2005, 26:241–249. CrossRef
- Kragelund C, Gronning B, Kober L, et al.: N-terminal pro-b-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005, 352:666–675. CrossRef
- • Morrow DA, de Lemos JA, Blazing MA, et al.: Prognostic value of B-type natriuretic peptide during follow-up of patients with unstable coronary artery disease in the A to Z trial. JAMA 2005, 294:2866–2871. Among patients with elevated BNP levels on presentation of ACS, the risk of mortality and CHF was highest among those with persistently elevated BNP at 4 months after the event. It was also found that a new elevation of BNP at 4 months postevent was associated with increased risk despite an initially normal concentration, and that BNP elevation that had resolved by 4 months only conferred a modest increase in risk CrossRef
- Goldstein JA, Chandra HR, O#x2019;Neill WW. Relation of number of complex lesions to serum C-reactive protein levels and major adverse cardiovascular events at one year. Am J Cardiol 2005, 96:56–60. CrossRef
- Oltrona L, Ottani F, Galvani M, et al.: Clinical significance of a single measurement of troponin-I and C-reactive protein at admission in 1773 consecutive patients with acute coronary syndromes. Am Heart J 2004, 148:405–415. CrossRef
- Ray KK, Cannon CP, Cairns R, et al.: Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol 2005, 46:1417–1424. CrossRef
- Bar-Or D, Lau E, Winkler JV: A novel assay for cobalt-albumin biding and its potential as a marker for myocardial ischemia — a preliminary report. J Emerg Med 2000, 19:311–315. CrossRef
- Roy D, Quiles J, Aldama G, et al.: Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 2004, 97:297–301. CrossRef
- Abadiel JM, Blassingame CL, Bankson DD: Albumin cobalt binding assay to rule out acute coronary syndrome. Ann Clinical Lab Sci 2005, 35:66–72.
- Jin Y, Nonoyama S, Morio T, et al.: Characterization of soluble CD40 ligand released from human activated platelets. J Med Den Sci 2001, 48:23–27.
- Yan JC, Wu ZG, Zong RQ, et al.: Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome. Acta Pharmacol Sin 2004, 25:251–256.
- • de Lemos JA, Zirlik A, Schönbeck U, et al.: Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005, 25:2192–2196.A large, stable, ambulatory, and multiethnic population was investigated, and it was found that sCD40L levels did not correlate with any classic CAD risk factors, nor did they correlate with any objective evidence of atherosclerotic disease by coronary calcium or aortic plaque CrossRef
- Bayes-Genis A, Conover CA, Overgaard MT, et al.: Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001, 345:1022–1029. CrossRef
- Heeschen C, Dimmeler S, Hamm CW, et al.: Pregnancyassociated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 2005, 45:229–237. CrossRef
- Cosin-Sales J, Christiansen M, Kaminski P, et al.: Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 2004, 109:1724–1728. CrossRef
- Carmeliet P, Moons L, Luttun A, et al.: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7:575–583. CrossRef
- Luttun A, Tjwa M, Moons L, et al.: Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002, 8:831–840.
- Heeschen C, Dimmeler S, Fichtlscherer, et al.: Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004, 291:435–441. CrossRef
- Komatsu S, Hirayama A, Omori Y, et al.: Detection of coronary plaque by computed tomography with a novel plaque analysis system, ‘Plaque Map’, and comparison with intravascular ultrasound and angioscopy. Circ J 2005, 69:72–77. CrossRef
- Inoue F, Sato Y, Matsumoto N, et al.: Evaluation of plaque texture by means of multislice computed tomography in patients with acute coronary syndrome and stable angina. Circ J 2004, 68:840–844. CrossRef
- Weston P, Alexander JH, Patel MR, et al.: Hand-held echocardiographic examination of patients with symptoms of acute coronary syndromes in the emergency department: the 30-day outcome associated with normal left ventricular wall motion. Am Heart J 2004, 148:1096–1101. CrossRef
- Korosoglou G, Labadze N, Hansen A, et al.: Usefulness of real-time myocardial perfusion imaging in the evaluation of patients with first time chest pain. Am J Cardiol 2004, 94:1225–1231. CrossRef
- Current status of risk stratification methods in acute coronary syndromes
Current Cardiology Reports
Volume 8, Issue 4 , pp 282-288
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links